Topic:
Clinical Trials
Latest Headlines
Latest Headlines
Chelsea scuttles rheumatoid arthritis drug after PhII failure, shares plunge
The developer says that its rheumatoid arthritis candidate CH-4051 failed to outperform the standard of care for the disease in a mid-stage study, forcing it to ax the program.
New CRO Agility Clinical to focus on pediatric and orphan diseases
A newly formed contract research organization in California is hoping to set itself apart from competitors by focusing the bulk of its work on combating pediatric and orphan diseases.
Lundbeck touts success of mid-stage Alzheimer's study
Lundbeck is touting mid-stage data underscoring the effectiveness of its experimental Alzheimer's drug Lu AE58054 for improving cognition and the quality of life for patients.
Trial vets at Flexion claim PhII success with lead osteoarthritis drug
This morning, Flexion announced that they hit the proof-of-concept stage as planned. Top-line results demonstrated that the intra-articularly delivered FX005 hit its primary endpoint on pain relief and function among osteoarthritis patients.
Sanofi/Regeneron add to stockpile of promising PCSK9 LDL drug data
Over the long Memorial Day, weekend Regeneron Pharmaceuticals ($REGN) and Sanofi ($SNY) added to their stockpile of promising mid-stage data for their PCSK9 drug, which is designed to slash levels of "bad" LDL-cholesterol.
Bungled analysis forces Vertex to revise cystic fibrosis drug data
Vertex shares took a nasty tumble this morning, freefalling 18% on the news that the company was forced to revise the data on its closely watched cystic fibrosis combo therapy after learning that the initial interim data report had been bungled.
Celldex scores upbeat data for breast cancer drug
The Needham, MA-based company's CDX-011 consists of an antibody targeted to the GPNMB protein and an attached chemotherapy agent that is supposed to hit tumor cells with a killer punch.
MediciNova shares crash after lead asthma drug fails IIb trial
While the CEO tried to put the data in context, offering reasons for optimism for a planned late-stage study of the lead program, investors watched the stock price crater more than 50% after the news hit.
Quintiles survey shows U.S. and U.K. payers want to improve R&D with increased involvement
Based on the findings published in Quintiles' annual "New Health Report," payers want to get the ball rolling sooner to get drugs approved faster.
Halo garners support for PhII DMD study
Halo wants to launch a Phase II for HT-100, an oral drug designed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients, in the second half of this year.
